International Journal of Gynecology & Obstetrics

A New Device Reduces Uterine Bleeding Suffered by One in Three Women of Reproductive Age

Retrieved on: 
Friday, April 28, 2023
Depression, Bleeding, Obstetrics, Hospital, Absenteeism, Quality of life, Woman, Cramp, Gynaecology, Abdominal pain, Uterus, La Mega Media, Pain, Congress, Cyclic permutation, SEAD, Canadian International Council, Risk, Anemia, Sport, International Journal of Gynecology & Obstetrics, Patient, Health, Birth control, Hysteroscopy

SITGES, Spain, April 28, 2023 /PRNewswire/ -- A new device has been presented at the 4th World Congress of Hysteroscopy in Sitges (Barcelona), which brings together 1,000 women's health specialists, allows for the reduction of abnormal uterine bleeding that affects one in three women of reproductive age and limits their quality of life.

Key Points: 
  • "Abnormal uterine bleeding is one of the main reasons for consultation in gynecology.
  • In this regard, a study published in the International Journal of Gynecology and Obstetrics found that women who experienced abnormal uterine bleeding had more days of work absenteeism than those who did not.
  • Other studies have shown that 4 out of 10 women suffer from depression as a result of these periods.
  • This minimally invasive procedure uses a spherical device to remove the lining of the uterus and reduce the amount of menstrual bleeding.

Four Year Study Shows Sustainable Long-Term Success for EnPlace® Minimally Invasive Meshless Approach to Pelvic Floor Ligament Fixation

Retrieved on: 
Tuesday, September 13, 2022
International Journal of Gynecology & Obstetrics, Woman, FDA, Canadian International Council, Holon, Wolfson Medical Center, Discrete least squares meshless method, Gynaecology, Patient, Dissection, Ligament, Obstetrics, Pelvic organ prolapse, Pelvic pain, Ageing, Dyspareunia, Multimedia, POP, Pelvic floor, Medicine, Birth control, Medical imaging, Hospital, EU

NEWARK, Del., Sept. 13, 2022 /PRNewswire/ -- FEMSelect, the developer of EnPlace, a minimallyinvasive,meshless approach to pelvic floor ligament fixation, reported positive results in a four-year prospective follow-up evaluation of the system.

Key Points: 
  • NEWARK, Del., Sept. 13, 2022 /PRNewswire/ -- FEMSelect, the developer of EnPlace, a minimallyinvasive,meshless approach to pelvic floor ligament fixation, reported positive results in a four-year prospective follow-up evaluation of the system.
  • Medical investigators found that EnPlace, cleared by the FDA for attaching sutures to ligaments of the pelvic floor, produced long-term apical repair success for women treated by this method.
  • The post-procedure impact showed a surgical success rate of 92.3% for the 13 women aged 48 through 82 who suffered from advanced Pelvic Organ Prolapse (POP).
  • FEMSelect's patented delivery system enables the precise guidance, insertion and deployment of a small, nitinol anchor for pelvic floor ligament fixation.

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

Retrieved on: 
Wednesday, May 18, 2022
Cancer, Hapten, Disease, HCL, Ovarian cancer, European Society of Gynaecological Oncology, Center, EMA, Standard of care, Immune system, FRA, OTCQB, University Hospital Center Dr Dragiša Mišović, GMP, Woman, Clinical trial, COVID-19, CSE, III, Hospital, Neoplasm, Company, Survival, Peritoneum, Doctor of Philosophy, Vaccine, Trial of the century, FDA, Obstetrics, Biotechnology, Good, Toxicity, CTA, European Medicines Agency, Heart, Hospices Civils de Lyon, Protein, Severe acute respiratory syndrome coronavirus 2, Cryopreservation, Patient, International Journal of Gynecology & Obstetrics, National Cancer Institute, IND, European Society for Clinical Investigation, Prognosis, Head, ProCare, Usha Menon, Pharmaceutical industry, Medical imaging, Lyon Metropolis, MD, EU, BC

HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.

Key Points: 
  • HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.
  • Benot You, MD, PhD, of HCL who are planned Clinical Investigators for the Phase I study of BVX-0918.
  • BioVaxys is preparing to file a Clinical Trial Application ("CTA") with the European Medicines Agency ("EMA") later in 2022.
  • Access to surgically removed ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918.

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

Retrieved on: 
Wednesday, May 18, 2022
Cancer, Hapten, Disease, HCL, Ovarian cancer, European Society of Gynaecological Oncology, Center, EMA, Standard of care, Immune system, FRA, OTCQB, University Hospital Center Dr Dragiša Mišović, GMP, Woman, Clinical trial, COVID-19, CSE, III, Hospital, Neoplasm, Company, Survival, Peritoneum, Doctor of Philosophy, Vaccine, Trial of the century, FDA, Obstetrics, Biotechnology, Good, Toxicity, CTA, European Medicines Agency, Heart, Hospices Civils de Lyon, Protein, Severe acute respiratory syndrome coronavirus 2, Cryopreservation, Patient, International Journal of Gynecology & Obstetrics, National Cancer Institute, IND, European Society for Clinical Investigation, Prognosis, Head, ProCare, Usha Menon, Pharmaceutical industry, Medical imaging, Lyon Metropolis, MD, EU, BC

HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.

Key Points: 
  • HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.
  • Benot You, MD, PhD, of HCL who are planned Clinical Investigators for the Phase I study of BVX-0918.
  • BioVaxys is preparing to file a Clinical Trial Application ("CTA") with the European Medicines Agency ("EMA") later in 2022.
  • Access to surgically removed ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918.